Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 159,662 shares at $132.93 ($20.7M) on 2023-05-24, disclosed to the SEC on 2023-05-26.
Scheduled sale ($20.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $131.13 | 28,144 | $3.7M | 17.9% |
| 2 | $131.13 | 28,144 | $3.7M | 17.9% |
| 3 | $131.98 | 9,820 | $1.3M | 6.3% |
| 4 | $131.98 | 9,820 | $1.3M | 6.3% |
| 5 | $132.93 | 2,036 | $271K | 1.3% |
| 6 | $132.93 | 2,036 |
| $271K |
| 1.3% |
| 7 | $126.32 | 10,367 | $1.3M | 6.3% |
| 8 | $126.32 | 10,367 | $1.3M | 6.3% |
| 9 | $127.45 | 20,641 | $2.6M | 12.7% |
| 10 | $127.45 | 20,641 | $2.6M | 12.7% |
| 11 | $128.33 | 8,654 | $1.1M | 5.4% |
| 12 | $128.33 | 8,654 | $1.1M | 5.4% |
| 13 | $128.99 | 338 | $44K | 0.2% |
| Total | $129.40 avg | 159,662 | $20.7M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |